Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-06-14 |
2024-04 |
0 |
-1.36 |
N/A |
N/A |
2024-03-13 |
2024-01 |
0 |
-0.08 |
N/A |
N/A |
2023-12-14 |
2023-10 |
0 |
-0.08 |
N/A |
N/A |
2023-10-30 |
2023-07 |
0 |
0.06 |
N/A |
N/A |
2023-06-13 |
2023-04 |
0 |
-0.06 |
N/A |
N/A |
2023-03-14 |
2023-01 |
0 |
-0.13 |
N/A |
N/A |
Date |
Name |
Relation |
Quantity |
Description |
2023-10-24 |
CONKLING WILLIAM |
Chief Executive Officer |
563.12K |
Stock Award(Grant) |
2022-01-31 |
FABBIO PATRICK |
President |
363.10K |
Stock Award(Grant) |
2024-01-04 |
GREENBERG STEPHEN M |
Director |
74.95K |
Stock Award(Grant) |
2022-08-08 |
I9 PLUS, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security |
3.23M |
Sale |
2024-06-12 |
JONAS HOWARD S |
Officer and Director |
4.05M |
Stock Award(Grant) |
2022-01-04 |
KLINGER SHANNON THYME |
Director |
5.41K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Group Inc |
549.88K |
1.15M |
2.34% |
2023-06-29 |
Dimensional Fund Advisors LP |
389.47K |
814.00K |
1.66% |
2023-06-29 |
Kahn Brothers Group Inc. |
275.24K |
575.24K |
1.17% |
2023-06-29 |
Acuitas Investments LLC |
233.42K |
487.86K |
0.99% |
2023-06-29 |
Blackrock Inc. |
193.44K |
404.29K |
0.82% |
2023-06-29 |
Renaissance Technologies, LLC |
135.32K |
282.81K |
0.58% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
381.61K |
797.57K |
1.62% |
2023-06-29 |
Vanguard Extended Market Index Fund |
147.73K |
308.76K |
0.63% |
2023-07-30 |
DFA U.S. Micro Cap Series |
114.20K |
228.39K |
0.49% |
2023-05-30 |
Fidelity Extended Market Index Fund |
53.42K |
108.97K |
0.23% |
2023-06-29 |
Bridgeway Funds Inc-Ultra Small Company Market Fund |
51.66K |
107.96K |
0.22% |
2023-07-30 |
DFA U.S. Core Equity 2 Portfolio |
38.64K |
77.28K |
0.16% |
Dividend |
Date |
0.02 |
2009-12-18 |
0.02 |
2009-06-19 |